Bone mineral density as a surrogate biomarker for fracture risk reduction - Authors' reply

Affiliations

¹ Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Dennis.Black@UCSF.EDU.
² Center for Advanced Orthopedic Studies, Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
³ Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
⁴ Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK.

Comment

Dennis M Black et al. Lancet Diabetes Endocrinol. 2020 Nov.

. 2020 Nov;8(11):876.

doi: 10.1016/S2213-8587(20)30340-5.

¹ Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Dennis.Black@UCSF.EDU.
² Center for Advanced Orthopedic Studies, Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
³ Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
⁴ Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK.

No abstract available

Comment on

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.
Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML; Foundation for the National Institutes of Health Bone Quality Project. Black DM, et al. Lancet Diabetes Endocrinol. 2020 Aug;8(8):672-682. doi: 10.1016/S2213-8587(20)30159-5. Lancet Diabetes Endocrinol. 2020. PMID: 32707115
Bone mineral density as a surrogate biomarker for fracture risk reduction.
Shah VN. Shah VN. Lancet Diabetes Endocrinol. 2020 Nov;8(11):875. doi: 10.1016/S2213-8587(20)30338-7. Lancet Diabetes Endocrinol. 2020. PMID: 33065054 No abstract available.
Bone mineral density as a surrogate biomarker for fracture risk reduction.
Lima JG, Nóbrega LHC, Santos MCF, Simas BCC. Lima JG, et al. Lancet Diabetes Endocrinol. 2020 Nov;8(11):875-876. doi: 10.1016/S2213-8587(20)30339-9. Lancet Diabetes Endocrinol. 2020. PMID: 33065055 No abstract available.